格隆汇2月9日丨劲方医药-B(02595.HK)公告，股东于股东特别大会上通过特别决议案以批准取消监事会 及修订组织章程细则。因此，自2026年2月9日起，公司将不再设有监事会，现任监事会成员不再担任监 事；及经修订组织章程细则将自股东特别大会当日起生效。 ...

勁方醫藥科技（上海）股份有限公司 章 程 （經於2026年2月9日舉行的臨時股東會審議及批准） | 目錄 | | --- | | 第一章 | 總則 | | 2 | | --- | --- | --- | --- | | 第二章 | | 經營宗旨和範圍 | 3 | | 第三章 | 股份 | | 4 | | 第一節 | | 股份發行 | 4 | | 第二節 | | 股份增減和回購 | 8 | | 第三節 | | 股份轉讓 | 10 | | 第四章 | | 股東和股東會 | 11 | | 第一節 | | 股東 | 11 | | 第二節 | | 股東會的一般規定 | 17 | | 第三節 | | 股東會的召集 | 19 | | 第四節 | | 股東會的提案與通知 | 21 | | 第五節 | | 股東會的召開 | 22 | | 第六節 | | 股東會的表決和決議 | 25 | | 第五章 | 董事會 | | 30 | | 第一節 | | 董事 | 30 | | 第二節 | | 董事會 | 34 | | 第六章 | | 高級管理人員 | 38 | | 第七章 | | 財務會計制度、利潤分配和審計 | 39 | | 第一 ...

茲提述勁方醫藥科技（上海）股份有限公司（「本公司」）發佈的日期均為2026年1月 23日的(i)通函（「通函」）及(ii)通告（「通告」），內容有關本公司股東特別大會（「股 東特別大會」）。除文義另有所指外，本公告所用詞彙與通函所界定者具有相同涵 義。 股東特別大會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2595） (1) 於2026年2月9日舉行的股東特別大會投票表決結果；及 (2) 取消監事會及修訂組織章程細則 (1) 有關決議案全文請參閱通函。特別決議案須以出席股東特別大會股東（包括其代理人）所 持表決權的至少三分之二通過。 由於股東（包括其代理人及授權代表）以超過三分之二的票數投票贊成第1至7項特 別決議案，故第1至7項特別決議案於股東特別大會上以投票表決方式獲正式通過 為 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02595 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 338,029,020 | RMB | | 0.1 RMB | | | 33,802,902 | | 增加 / 減少 (-) | | | | | | RMB | | | | | 本月底結存 | | | 338,029,020 | RMB | | 0.1 RMB | | | 33,802,902 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 ( ...

Core Viewpoint - The report by CMB International initiates coverage of Jinfang Pharmaceutical-B (02595) with a "Buy" rating and a target price of HKD 51, highlighting the company's strong management team and innovative drug pipeline focused on challenging RAS targets [1] Group 1: Product Pipeline and Innovation - The company has developed a diversified product pipeline centered around the difficult-to-drug RAS family members, leveraging deep understanding and successful R&D experience to create a candidate matrix that includes KRASG12C/G12D and pan-RAS, among others [2] - The product pipeline extends beyond RAS targets to include other significant indications such as tumors, cachexia, autoimmune, and inflammatory diseases, targeting market opportunities with favorable competitive landscapes [2] Group 2: Clinical Data and Competitive Advantage - The competitive advantage in RAS-targeted drug development is evident in the clinical data for GFH925 and GFH375, with GFH925 showing superior efficacy in 2L+ KRASG12C mutation NSCLC compared to overseas competitors and comparable or better results against domestic rivals [3] - GFH375 is among the first globally to enter Phase III clinical trials for KRASG12D, with promising preliminary data in third-line pancreatic cancer [3] - The dual antibody GDF15/IL-16 (GFS202A) shows early advantages in tolerability and activity compared to single-target drugs [3] Group 3: Management and Strategic Partnerships - The company has assembled a core management team with an average of over 20 years of industry experience, achieving a record of six years from project initiation to market launch for GFH925 [4] - The company actively seeks diverse global development opportunities and strategically selects partners to create value through complementary strengths, collaborating with notable firms such as Innovent Biologics, Merck, and Verastem [4] Group 4: Financial Projections and Valuation - The company is projected to achieve revenues of RMB 1.09 billion, 0.85 billion, and 1.18 billion in 2025-2027, primarily driven by sales of GFH925 in China and overseas collaboration for GFH375 [5] - Based on a DCF valuation model, the target price of HKD 51 corresponds to a 2.3x revenue peak sales multiple and an 87% potential upside [5] - Future focus includes monitoring the sales ramp-up of GFH925 post-reimbursement inclusion and additional data readouts from the RAS pipeline [5]

Core Viewpoint - The report by CMB International initiates coverage of Jinfang Pharmaceutical-B (02595) with a "Buy" rating and a target price of HKD 51, highlighting the company's innovative drug pipeline and strong management team [1] Group 1: Product Pipeline and Innovation - The company has established a diversified product pipeline focused on challenging RAS targets, leveraging deep understanding and successful development experience to create a candidate matrix that includes KRASG12C/G12D and pan-RAS, among others [1] - GFH925 (Fuzeracib) has been approved for marketing in mainland China, marking it as the first domestic product targeting the same RAS family member [1] - The product pipeline also extends to other significant indications such as tumors, cachexia, autoimmune, and inflammatory diseases, targeting promising areas like RIPK1 and GDF15/IL-6 [1] Group 2: Clinical Data and Competitive Advantage - The company demonstrates a competitive edge in RAS-targeted drug development, with GFH925 showing excellent efficacy in 2L+ KRASG12C mutation non-small cell lung cancer (NSCLC) patients, outperforming overseas competitors [2] - GFH375 is among the first globally to enter Phase III clinical trials for KRASG12D, showing promising initial data compared to major competitors [2] - The dual antibody GFS202A targeting GDF15/IL-16 is progressing rapidly, with early signs of tolerability and activity advantages over single-target drugs [2] Group 3: Management and Strategic Partnerships - The company has assembled a core management team with an average of over 20 years of industry experience, achieving a record of six years from project initiation to market launch for GFH925 [3] - The company actively seeks diverse global development opportunities and strategically selects partners to create value through complementary strengths, collaborating with notable firms such as Innovent Biologics, Merck, and Verastem [3] Group 4: Financial Projections and Valuation - The company is projected to achieve revenues of RMB 1.09 billion, 0.85 billion, and 1.18 billion in 2025-2027, primarily driven by sales of GFH925 in mainland China and overseas collaboration income from GFH375 [4] - Using a DCF valuation model, the target price of HKD 51 corresponds to a 2.3x peak revenue sales multiple and an 87% potential upside [4] - Future focus will be on the sales ramp-up of GFH925 post-inclusion in medical insurance and additional data readouts from the RAS pipeline [4]

GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2595） 將於2026年2月9日（星期一）舉行的股東特別大會的代表委任表格 本人╱吾等 （附註1） 1. 請用正楷填上全名及地址（須與本公司股東名冊所登記相同）。 2. 請填上與本代表委任表格有關以 閣下名義登記的股份數目。倘未填入股份數目，則本代表委任表格將被視為與以 閣下名義登記的所有股 份有關。 3. 請刪去與本代表委任表格無關的股份類別（未上市股份或H股）。 4. 如欲委任大會主席以外的任何代表，請刪去「大會主席或」字樣，並在空格處填上擬委任的代表姓名及地址。有權出席股東特別大會並於會 上投票的股東可委任一名或多名代表代其出席並投票。受委代表毋須為本公司股東，但須親身代表 閣下出席股東特別大會。該等受委代表 僅可於按股數投票時方可行使其表決權。本代表委任表格的每項更改，均須由簽署人簡簽示可。 5. 注意：閣下如欲投票贊成決議案，請在「贊成」欄內填上「✓」號； 閣下如欲投票反對決議案，請在「反對」欄內填上「✓」號。 閣下如欲放棄 投票，請 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本通告全部或任何部分內容而產生或因依賴該等內容引致的任何損 失承擔任何責任。 GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2595） 股東特別大會通告 茲通告勁方醫藥科技（上海）股份有限公司（「本公司」）謹訂於2026年2月9日（星 期一）上午十時正假座中國（上海）自由貿易試驗區張江路1206號A幢212室舉行股東特 別大會（「股東特別大會」）或其任何續會，藉以考慮並酌情通過（不論是否作出修訂）本 公司以下決議案（除另有所指外，本通告所用詞彙與本公司日期為2026年1月23日的通 函所界定者具有相同涵義）： 特別決議案 「動議： (a) 在下文(b)段的規限下，一般性及無條件地批准董事於有關期間（定義 見下文）行使本公司的一切權力，按照及根據一切適用法律及上市規 則，在香港聯合交易所有限公司（「聯交所」）或任何本公司股份可能 上市並就此獲證券及期貨事務監察委員會及 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問，應諮詢股票經紀或其他註冊證券商、銀行經理、律 師、專業會計師或其他專業顧問。 閣下如已出售或轉讓名下所有勁方醫藥科技（上海）股份有限公司的股份，應立即將本通函連同代表委任 表格送交買主或承讓人，或經手買賣或轉讓的銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本通函全部或任何部分內容而產生或因依賴該等內容而引致的任 何損失承擔任何責任。 警示：本通函內容未經任何香港監管機構審閱。敬請 閣下謹慎留意購股權及獎勵的授出。如對本通函任 何內容有任何疑問， 閣下應獲取獨立專業意見。 GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2595） (1) 建議採納H股購股權計劃 (2) 建議採納H股股份激勵計劃 (3) 建議授權董事會及╱或授權人士處理與股份計劃有關的事宜 (4) 建議授出一般授權以購回H股 ...

Core Insights - The introduction of new pricing for lung cancer drugs, particularly the KRAS G12C inhibitors, has significantly reduced costs for patients, with prices dropping by nearly 70% for some medications [2][4][7] - The 2025 medical insurance directory includes 50 innovative drugs, with nearly half being cancer treatments, highlighting a focus on unmet clinical needs [2] - The competitive landscape for KRAS G12C inhibitors is intensifying, with companies now competing on clinical efficacy and commercial execution rather than just pricing [5][7][8] Pricing and Market Impact - The price of Fluorouracil has decreased from approximately 24,900 yuan to 5,790.4 yuan per box, resulting in a 68.87% reduction [7] - Patients previously faced annual treatment costs of 223,200 yuan, which can now be reduced to approximately 20,845.44 yuan after insurance reimbursement, saving over 200,000 yuan annually [4] - The entry of these drugs into the insurance system is expected to reshape market dynamics and increase competition among pharmaceutical companies [4][8] Competitive Landscape - The KRAS G12C inhibitors market is characterized by three main products: Fluorouracil, Goresir, and Gexoriser, all approved for similar indications, creating a "three-legged" competitive structure [6] - The market for KRAS G12C inhibitors is not overly saturated, with the mutation occurring in about 14% of non-small cell lung cancer cases, and approximately 4.3% in the Chinese population [6] - Companies are focusing on differentiating their products through clinical evidence and effective management of side effects to establish a preferred choice among doctors and patients [7][8] Future Directions - Companies are exploring combination therapies and expanding indications beyond non-small cell lung cancer to other cancers like colorectal and pancreatic cancer, which may significantly increase market potential [13] - The focus on overcoming drug resistance and enhancing efficacy through partnerships and global market strategies is seen as essential for long-term success [13] - The competitive focus is shifting towards who can provide better clinical outcomes and safety profiles, indicating a new phase in the market dynamics for KRAS G12C inhibitors [7][8]